摘要
目的比较VTD(硼替佐米+沙利度胺+地塞米松)方案与VAD(长春新碱+表柔比星+地塞米松)方案治疗多发性骨髓瘤(MM)的临床效果。方法系统回顾我院2015年1月—2019年8月收治的50例多发性骨髓瘤(MM),按治疗方案不同分成VTD组和VAD组,比较两组患者的疗效、不良反应、骨痛评分及血钙磷水平。结果VTD患者方案组的治疗总有效率为81.82%,VAD组的治疗总有效率为64.29%,VTD组治疗总有效率高于VAD组,两组之间差异有统计学意义(χ^2=9.248,P=0.031<0.05)。VTD组的白细胞/血小板减少发生率和胃肠道反应发生率显著低于VAD组,差异有统计学意义(P<0.05)。VTD组治疗后骨痛评分明显低于VAD组,组间比较差异有统计学意义(P<0.05)。VTD组和VAD组治疗前后的血钙和血磷水平比较均差异无统计学意义(P>0.05)。结论对于多发性骨髓瘤治疗中,VTD方案较传统的VAD方案具有良好的治疗效果,值得临床推广。
Objective To compare the clinical effects of VTD(bortezomib+thalidomide+dexamethasone)regimen and VAD(vincristine+epirubicin+dexamethasone)in the treatment of multiple myeloma(MM).Methods Fifty patients with multiple myeloma(MM)admitted to the hospital from January 2015 to August 2019 were divided into VTD group and VAD group according to different treatment options.The efficacy,adverse reactions and bone pain,blood calcium and phosphorus levels scores of the two groups were compared.Results The total effective rate was 81.82%in the VTD group and 64.29%in the VAD group.The total effective rate in the VTD group was higher than that in the VAD group.The difference between the two groups was statistically significant(χ^2=9.248,P=0.031<0.05).The incidence of leukocyte/thrombocytopenia and gastrointestinal reaction in the VTD group was significantly lower than that in the VAD group,and the difference was statistically significant(P<0.05).The bone pain scores in the VTD group were significantly lower than those in the VAD group,and the difference between the groups was statistically significant(P<0.05).There were no statistically significant differences in serum calcium and serum phosphorus levels between the VTD group and the VAD group(P>0.05).Conclusion For the treatment of multiple myeloma,the VTD regimen has a better therapeutic effect than the traditional VAD regimen and is worthy of clinical promotion.
作者
曹春燕
CAO Chun-yan(Department of Hematology,Tongzhou District People's Hospital,Nantong,Jiangsu Province,226300 China)
出处
《中外医疗》
2019年第35期94-96,共3页
China & Foreign Medical Treatment
